Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...
Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...
The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...
As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...
Top large-cap gainers for Dec. 15–19 were led by Rivian, Moderna, and BioMarin, rising on product/software updates, vaccine ...
Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...
The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...
Moderna (NASDAQ: MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29 ...
The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback